Co-Authors
This is a "connection" page, showing publications co-authored by MIMI I-NAN HU and VIVEK SUBBIAH.
Connection Strength
1.481
-
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol. 2024 Mar 04; 8(1):62.
Score: 0.238
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
Score: 0.235
-
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med. 2023 12 19; 4(12):101332.
Score: 0.235
-
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
Score: 0.197
-
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799.
Score: 0.188
-
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849.
Score: 0.158
-
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132.
Score: 0.055
-
Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12.
Score: 0.047
-
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.
Score: 0.044
-
Vandetanib photoinduced cutaneous toxicities. Cutis. 2019 May; 103(5):E24-E29.
Score: 0.043
-
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
Score: 0.041